Introduction {#s1}
============

Auditory neuropathy spectrum disorder (ANSD) is characterised by absent or severely abnormal inner hair cell (IHC) function as measured by auditory brainstem responses (ABRs), with preservation of outer hair cell (OHC) function as indicated by otoacoustic emission (OAE) and/or cochlear microphonic (CM) testing. First described by Starr *et al* in 1996,[@R1] patients with ANSD present with variable degrees of unilateral or bilateral hearing impairment accompanied by poor speech discrimination and poor word understanding especially in the presence of noise. The prevalence of ANSD varies from 0.5% to 15% among hearing-impaired patients, with an incidence of about 13% in children with severe-to-profound hearing loss.[@R2] Consistent with physiological tests of auditory function, ANSD can be caused by lesions of the IHC, IHC--auditory nerve synapse, auditory nerve or auditory cortex.[@R5]

In many cases of ANSD, the molecular pathology remains unclear, with underlying aetiologies running the gamut of genetic abnormalities, toxic/metabolic derangements, infections, immunological causes and drugs.[@R8] [@R9] Forty per cent of ANSD is estimated to have a genetic basis with autosomal-dominant, autosomal-recessive, mitochondrial and X-linked inheritance all reported.[@R3] The list of causative genes includes *OTOF*, *PJVK*, *DIAPH3* and *mtDNA* (*m.1095T\>C*) in non-syndromic ANSD and *PMP22*, *MPZ*, *TMEM126A* and *DDDP* in syndromic ANSD, although other genetic aetiologies await discovery.[@R2]

In 2006, we reported a large Chinese family with X-linked progressive auditory and peripheral sensory neuropathy, and mapped this ANSD locus (AUNX1) to chrXq23-27.3.[@R10] Using whole-exome sequencing (WES), we have identified the causal AUNX1 gene as *AIFM1* and show that variants in this gene are a common cause of familial and sporadic ANSD. This finding is noteworthy because *AIFM1* mutations are also associated with mitochondrial encephalomyopathy, prenatal ventriculomegaly and Cowchock syndrome, three disorders characterised by developmental disabilities, motor dysfunction, muscle weakness and brain abnormalities as resolved by MRI.[@R11] Our work expands the spectrum of *AIFM1*-associated phenotypes and mandates screening of *AIFM1* in small pedigrees with apparent autosomal-recessive ANSD if X-linked inheritance cannot be excluded.

Methods {#s2}
=======

Family ascertainment and clinical evaluation {#s2a}
--------------------------------------------

Five unrelated Chinese families (AUNX1, 7170, 0223, 2724 and 2423) and 93 sporadic male patients diagnosed with ANSD were ascertained through the Department of Otolaryngology, Head and Neck Surgery, Chinese PLA General Hospital, from November 2000 to June 2014. The phenotype of the AUNX1 family has been reported and includes auditory neuropathy and delayed peripheral sensory neuropathy inherited in an X-linked recessive pattern. The other four families had a similar clinical phenotype. In all cases, genes commonly involved in ANSD such as *OTOF*, *PJVK* and *DIAPH3* were excluded by Sanger sequencing. Acquired causes of ANSD such as prematurity, hyperbilirubinemia, anoxia, hypoxia, congenital brain abnormalities, perinatal intracranial haemorrhage, asphyxia and ototoxic drug exposure were excluded by medical history.

All participants were examined by a multidisciplinary team of healthcare providers that included a neurologist, otolaryngologist and audiologist. The evaluation consisted of a comprehensive medical history, physical examination with careful clinical assessment for peripheral neuropathies, pure-tone audiometry, tympanometry, acoustic reflex testing, ABR, distortion-product OAE testing and electrocochleography. The diagnosis of ANSD was based on recognised criteria (Guidelines Development Conference at NHS 2008, Como, Italy). Neurological examinations included assessments of cranial nerve function, motor activity, muscle weakness, sensory impairment and reflexes. Electrophysiological studies including needle electromyography (EMG), nerve conduction velocity (NCV) and somatosensory evoked potential (SEP) in seven patients from the four unrelated families were carried out. The EMG was performed in the abductor pollicis brevis, tibialis anterior and vastus lateralis muscles. Motor nerve conduction velocities (MCVs) of tibial, peroneal, median and ulnar nerves, as well as sensory nerve conduction velocities (SCVs) of sural, median and ulnar nerves, were obtained. Amplitudes of compound muscle action potential (CMAPs) and sensory nerve action potential (SNAPs) were measured from positive to negative peak values. The Mini Mental State Examination (MMSE) on the three patients (III: 1, III: 9 and III: 11) of family 2423 was conducted to assess the cognitive function. Select patients underwent MRI of brain, temporal high-resolution CT and electrocardiography. Serum enzymes related to energy metabolism, such as lactate dehydrogenase and creatine kinase, were measured.

Peripheral blood samples were obtained and genomic DNA was extracted according to standard procedures. WES was performed on one person from the AUNX1 family (III: 12) and three persons from the 0223 family (II: 1, III: 1 and III: 3). Results were confirmed and validated by Sanger sequencing in these persons and other available family members ([figures 1B](#JMEDGENET2014102961F1){ref-type="fig"} and [2](#JMEDGENET2014102961F2){ref-type="fig"}A). Three other small families (7170, 2724 and 2423, [figure 2](#JMEDGENET2014102961F2){ref-type="fig"}B--D) and 93 unrelated sporadic cases with ANSD were analysed by Sanger sequencing. Five hundred ethnicity-matched individuals (250 men and 250 women) with normal hearing were recruited as normal controls.

![Identification of the disease-causing *AIFM1* mutation in the AUNX1 family segregating auditory and peripheral neuropathy. (A) Schematic genetic and physical map of the AUNX1 locus on chromosome Xq23-q27.3. The location of the *AIFM1* gene is indicated (Mb, million bps). (B) The phenotype in AUNX1 family co-segregates with the c.1352G\>A (p.R451Q) mutation in *AIFM1*. The genotypes at c.1352 for the family members are given: G or GG means hemi- or homozygous for the wild-type (WT) sequence, GA means c.1352G\>A heterozygous, and A denotes the mutation in hemizygous form. Whole-exome sequencing was completed on subject III: 12. (C) Sequence chromatograms of exon 13 of *AIFM1* show the c.1352G\>A (p.R451Q) mutation (arrowhead) in affected males (hemizygote) and female carriers (heterozygote). A homozygous WT sequence is shown on the bottom. (D) Multiple sequence alignment depicts evolutionary conservation of amino acid residue Arg451 (red vertical bar) across human, bovine, mouse, chicken, Xenopus and zebrafish.](jmedgenet-2014-102961f01){#JMEDGENET2014102961F1}

![The four auditory neuropathy spectrum disorder families segregating *AIFM1* mutations. Pedigree, sequence results and typical audiogram of each family are shown. Missense mutations c.1030C\>T (p.L344F), c.778A\>G (p.T260A), c.1264C\>T (p.R422W) and c.1265G\>A (p.R422Q) were identified in family 0223 (A), 7170 (B), 2724 (C) and 2423 (D), respectively. These mutations co-segregate with auditory and peripheral sensory neuropathy while carriers have normal hearing and sensory ability. The genotypes at c.1030, c.778, c.1264 and c.1265 for the available members in the corresponding family are given respectively. Whole-exome sequencing was completed on three persons in family 0223 (II: 1, III: 1 and III: 3). Needle electromyography and nerve conduction studies were performed on the individuals from family 7170 (IV: 2), family 0223 (III: 3), family 2724 (II: 4) and family 2423 (III: 1, III: 9 and III: 11). The Mini Mental State Examination was conducted on the three patients in family 2423 (III: 1, III: 9 and III: 11).](jmedgenet-2014-102961f02){#JMEDGENET2014102961F2}

Whole-exome sequencing {#s2b}
----------------------

Quantified, high-quality genomic DNA (2 µg per person) from one individual from family AUNX1 (III: 12) and three individuals from family 0223 (II: 1, III: 1 and III: 3) was used for WES. Each genomic DNA sample was captured using Agilent SureSelectXT Human All Exon V5 technology (Agilent Technologies, Santa Clara, California, USA) and enriched libraries were sequenced using the HiSeq 2000 platform (Illumina, San Diego, California, USA). Raw image files were processed on the Illumina Pipeline V.1.6 using default parameters, and sequences generated as 75--90 bp paired-end reads were aligned to NCBI37/hg19 assembly. Duplicate reads were removed using Picard (<http://picard.sourceforge.net>), and clean reads localised to the target region were collected and analysed by SOAPsnp (V.1.03).[@R14] Local realignment of insertions and deletions (indels) and variant annotation were performed using the Genome Analysis Toolkit (<http://www.broadinstitute.org/gatk/>).[@R15] By previously described criteria,[@R16] [@R17] the low-quality variations were filtered out.

Target enrichment was analysed using NGSrich.[@R18] Variants were filtered against 1000 Genomes data, and all variants with a minor allele frequency (MAF) \>1% were removed from the analysis. Functional annotation of genetic variants was performed using ANNOVAR (<http://www.openbioinformatics.org/annovar/>). Candidate variants were Sanger validated.

Mutation screening of *AIFM1* {#s2c}
-----------------------------

*AIFM1* (NC_000023.10) contains 16 exons. Thirty-two primers (16 primer pairs) were designed using Primer V.3.0 software and synthesised by Invitrogen by Life Technology (Beijing, China) to amplify each exon and exon--intron boundaries (see online supplementary table S1). PCR was performed with PE9700 thermocyclers (Applied Biosystems) using standard conditions. Amplified products from all ANSD cases and controls were gel purified and sequenced (ABI 3730, Applied Biosystems). Nucleotide alterations were identified by sequence alignment with the NCBI Reference Sequence (RefSeq) using DNAStar software V.5.0 (DNASTAR, Madison, Wisconsin, USA).

Evaluation of the pathogenicity {#s2d}
-------------------------------

Pathogenicity was assessed using PolyPhen-2 (Polymorphism Phenotyping V.2, <http://genetics.bwh.harvard.edu/pph2/index.shtml>), SIFT (<http://sift.jcvi.org/>), Protein Variation Effect Analyzer (PROVEAN) (<http://provean.jcvi.org/index.php>) and Mutation accessor (<http://mutationassessor.org/>).

Immunofluorescent staining in mouse inner ear {#s2e}
---------------------------------------------

All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University at Buffalo that conform to the guidelines issued by the National Institutes of Health. Adult mice (C57, 2 months of age) were used for immunofluorescence studies. The cochlear tissues of basilar membrane, spiral ligament and the vestibular end-organ of saccule macula were micro-dissected out as has been described.[@R19] [@R20] After incubation at 4°C for 24 h with 1% Triton X100 and 5% goat serum in 0.1 M phosphate buffered saline (PBS) containing AIF primary antibody (rabbit monoclonal antibody against AIF, 1:100, Cat\# ab32516, Abcam), the specimens were then incubated with tetramethylrhodamine isothiocyanate dextran-conjugated goat antirabbit secondary antibody (1:500, Cat\# F6005, Sigma) in PBS for 2 h at room temperature. The speciments were next immersed in Alexa-488-conjugated phalloindin (1:200, Cat\#A12379, Invitrogen) for 40 min to label the stereocilia and cuticular plate of the cochlear and vestibular sensory hair cells, and the F-actin in the gap-junction of marginal cells of stria vascularis. The nuclei of tissues were also labelled with 4′,6-diamidino-2-phenylindole dihydrochloride for 30 min. Immunoreactive products were observed under a confocal laser scanning microscope. As a negative control, the primary antibodies were omitted.

Results {#s3}
=======

Identification of missense mutations in *AIFM1* by WES {#s3a}
------------------------------------------------------

To identify the causative variant at the AUNX1 locus, we completed exome sequencing of the proband in family AUNX1. Ninety-nine variants were identified within the AUNX1 locus. After filtering out synonymous changes and variants found in \<85% of reads (inconsistent with X-linked inheritance in individual III: 12, an affected man), 24 variants remained: 17 non-synonymous variants, 2 in-frame indels and 5 frameshift indels. Based on incidence data for non-syndromic hearing loss and auditory neuropathy, we excluded variants with an MAF \>0.001.[@R21] [@R22] Three variants remained---*AIFM1* chrX 129267384:G\>A; *HS6ST2* chrX 131762528:G\>A and *VCX3A* chrX 6452043:C\>A---none of which are reported in the NHLBI Go Exome Sequencing Project (ESP) (6503 individuals) or the 1000 Genomes Project (1000G) (1092 individuals). Because *VCX3A* is expressed only in male germ cells, it was not considered further.[@R23] [@R24] Both of the remaining variants were confirmed in the proband by Sanger sequencing, but only AIFM1 p.R451Q co-segregated with the phenotype in the extended AUNX1 family (eight informative meioses were tested; [figure 1](#JMEDGENET2014102961F1){ref-type="fig"}A--C). This variant was not found in a screen of 500 normal-hearing ethnicity-matched controls (250 women, 250 men, 750 X chromosomes).

To identify the causative variant in the second family (0223), we completed exome sequencing of the proband (III: 1), his affected brother (III: 3) and unaffected father (II: 1). WES generated an average of 12.3 Gb of sequence, with at least 120× average coverage for each individual as paired-end, 90 bp reads, indicating the high quality of sequencing (see online supplementary figures S1 and S2 and table S2). After mapping to the reference genome sequence, \>99.0% of the targeted bases were covered sufficiently to pass quality assessment for calling single-nucleotide polymorphisms (SNPs) and short indels (see online supplementary table S2). We identified an average of ∼20 700 SNPs in coding regions (exonic), an average of 129 variants (SNPs and indels) within 2 bp of an exon/intron boundary that may affect splicing, and an average of 1270 indels in coding regions (see online supplementary table S3). Because the two affected individuals share the causal variant when compared with their normal-hearing father, a total of 807 variants were retained after filtering against SNP and Indel databases including dbSNP 141, 1000G, Hapmap 8 and YH (see online supplementary tables S4 and S5). Among them, 213 variants (including 129 non-synonymous SNPs and splice sites, as well as 84 indels) were predicted to have a functional impact (see online supplementary tables S6 and S7). Because inheritance was consistent with an autosomal or X-linked recessive pattern based on family pedigrees, candidate pathogenic variants selected for further analysis were rare homozygous or hemizygous nonsense, missense, splice site and indel variants with allele frequencies of ≤0.005 in public variant databases. Combined with the predicted effect on protein function by SIFT, PolyPhen2 and Mutation Assessor programs, we identified five variants (including one rare SNP and four indels) to be candidates (see online supplementary table S8). After Sanger sequencing and genotyping in all available family members, the only variant segregating with the phenotype (auditory and peripheral sensory neuropathy) of family 0223 was c.1030C\>T (p.L344F) in the AIFM1 gene ([figure 2](#JMEDGENET2014102961F2){ref-type="fig"}A). This variant is recorded in dbSNP (rs184474885, <http://www.ncbi.nlm.nih.gov/projects/SNP>) with a very low MAF (A=0.0005, 2/3775). Interestingly, although this variant is recorded as an SNP in 1000G, it was not found in the screen of 500 normal-hearing ethnicity-matched controls in Chinese populations (mentioned above).

Mutation spectrum of *AIFM1* in familial and sporadic ANSD {#s3b}
----------------------------------------------------------

To investigate the contribution of *AIFM1* to ANSD in China, we screened this gene for mutations in our extended familial and sporadic ANSD cohort; identifying 10 more novel missense mutations in three additional families and 11 of 93 (10%) men with an ANSD phenotype ([figure 3](#JMEDGENET2014102961F3){ref-type="fig"}, [table 1](#JMEDGENET2014102961TB1){ref-type="table"} and online [supplementary table](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2014-102961/-/DC1) S9). In all cases of familial ANSD, the identified missense mutations (c.778A\>G \[p.T260A\], c.1030C\>T \[p.L344F\], c.1264C\>T \[p.R422W\], c.1265G\>A \[p.R422Q\], c.1352G\>A \[p.R451Q\]) completely segregated with the auditory and peripheral sensory neuropathy phenotype, with female carriers not reporting any signs of ANSD or peripheral sensory neuropathy ([figures 1B](#JMEDGENET2014102961F1){ref-type="fig"} and [2](#JMEDGENET2014102961F2){ref-type="fig"}). Two variants identified in familial ANSD, c.1030C\>T (p.L344F) and c.1264C\>T (p.R422W), were also detected in sporadic ANSD cases, with similar phenotypes ([table 1](#JMEDGENET2014102961TB1){ref-type="table"}). All of the 10 additional *AIFM1* mutations were also absent in the screen of normal-hearing ethnicity-matched controls (750 X chromosomes). None of these variants were found in ESP or 1000G except c.1030C\>T (p.L344F) (see online supplementary table S10).

###### 

Summary of the clinical phenotypes for cases with AIFM1 mutations

  Cases ID                  7170\*                0223\*                  1302                   1757                    7187                   1747                   2724\*                 3033                   6962                   2423\*                 0077                   AUNX1\*    1806     0046       4678       3305
  ------------------------- --------------------- ----------------------- ---------------------- ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------- -------- ---------- ---------- --------
  Mutation† detected        c.778A\>G (p.T260A)   c.1030C\>T (p.L344F)‡   c.1078G\>C (p.G360R)   c.1264C\>T (p.R422W)§   c.1265G\>A (p.R422Q)   c.1288C\>T (p.R430C)   c.1352G\>A (p.R451Q)   c.1415C\>T (p.A472V)   c.1424C\>T (p.P475L)   c.1492G\>A (p.V498M)   c.1773C\>G (p.I591M)                                             
  Hearing loss degree¶      Mild                  Mild                    Mild                   Mild                    Moderate               Moderate               Moderate               Mild                   Mild                   Moderate               Mild                   Moderate   Mild     Moderate   Moderate   Mild
  Tinnitus                  \+                    −                       \+                     \+                      \+                     \+                     \+                     \+                     −                      \+                     −                      \+         \+       −          \+         \+
  Vertigo                   −                     −                       −                      −                       −                      −                      −                      −                      −                      −                      −                      −          −        −          −          −
  Unsteadiness              \+                    \+                      −                      −                       −                      \+                     \+                     \+                     −                      \+                     −                      \+         −        −          −          −
  Numbness of extremities   \+                    \+                      −                      \+                      −                      \+                     \+                     \+                     −                      \+                     −                      \+         −        −          −          −
  Visual impairment         −                     −                       −                      −                       −                      Myopia                 −                      −                      −                      Myopia                 −                      −          Myopia   −          −          Myopia
  Foot deformity            −                     −                       −                      −                       −                      −                      −                      −                      −                      −                      −                      −          −        −          −          −
  Muscle atrophy            −                     −                       −                      −                       −                      −                      −                      −                      −                      −                      −                      −          −        −          −          −
  Intellectual abilities    −                     −                       −                      −                       −                      −                      −                      −                      −                      −                      −                      −          −        −          −          −
  MRI of brain              CNH                   CNH                     NT                     NT                      CNH                    NT                     CNH                    NT                     NT                     CNH                    NT                     CNH        NT       NT         NT         CNH
  CT of temporal bone       −                     −                       NT                     NT                      −                      NT                     −                      −                      −                      −                      NT                     −          NT       NT         NT         −

\*Familial cases, representing the probands of the AN families. The other cases are sporadic cases.

†RefSeq: NM_004208.3, NP\_ NP_004199.1, GRCh38/hg38 chrX: NC_000023.11 (130129362..130165887, complement).

‡The mutation of c.1030C\>T (p.L344F) was detected not only in family 0223 but also in other three sporadic cases 1302, 1757 and 7187.

§The mutation of c.1264C\>T (p.R422W) was detected not only in family 2724 but also in the two sporadic cases 3033 and 6962.

¶The degrees of hearing loss were evaluated based on the recommendations of the EU HEAR project, as described by Stephens (2001), and the detailed audiological data of the auditory neuropathy spectrum disorder cases are summarised in online supplementary table S9.

+/−, positive or negative finding; CNH, cochlear nerve hypoplasia; NT, not tested.

![*AIFM1* mutation screening in patients with familial and sporadic auditory neuropathy spectrum disorder (ANSD) with or without peripheral neuropathy. Graphical representation of *AIFM1* structure (upper panel) and its encoded protein (lower panel). *AIFM1* gene has 16 exons. As a flavoprotein with an oxidoreductase enzymatic activity, AIFM1 contains a flavin adenine dinucleotide (FAD)-bipartite domain (in green), a reduced nicotinamide adenine dinucleotide (NADH)-binding motif (in orange) and a C-terminal domain (in grey). It also has a mitochondria localisation sequence (in blue) located in the N-terminal region (reference: <http://atlasgeneticsoncology.org//Genes/AIFM1ID44053chXq25.html>). The positions of 11 mutations identified in familial and sporadic ANSD cases are shown between the two diagrams (blue lines and red bars). The c.1352G\>A (p.R451Q) mutation identified in the AUNX1 family is located in exon 13, which corresponds to the second FAD domain. The longest isoform of *AIFM1* (NM_004208.3; NP_004199.1) was used as the reference sequence for mutation nomenclature.](jmedgenet-2014-102961f03){#JMEDGENET2014102961F3}

Clinical manifestations of *AIFM1*-associated ANSD {#s3c}
--------------------------------------------------

The phenotype associated with the AUNX1-causing *AIFM1* p.R451Q mutation is characterised by childhood-onset ANSD and delayed peripheral sensory neuropathy presenting as extremity numbness, unsteadiness and areflexia.[@R25] This clinical picture was seen with the other familial cases of *AIFM1* ANSD (0223, 7170, 2724 and 2423) and in some patients with sporadic *AIFM1* ANSD ([table 1](#JMEDGENET2014102961TB1){ref-type="table"} and online [supplementary table](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2014-102961/-/DC1) S9). The electrophysiological findings of 14 nerves in seven affected familial members were obtained (see online supplementary table S11). Nerve conduction studies demonstrated reduced sural, median and ulnar sensory NCVs or even absent responses. The reduced SCVs were always associated with reduced SNAPs (see online supplementary figure S3). The abnormal SEP results were also recorded, including no response or prolonged latency for the evoked potential P40 of tibial SEP, with or without prolonged latency of N9 potential of median SEP (see online supplementary figure S4). The data indicated that the patients might have demyelination changes in the peripheral sensory nerves. However, the MCVs and CMAPs of all patients were normal (see online supplementary figure S3). Needle EMG performed in these patients also showed normal values. There were no fibrillation, positive or fasciculation potentials and myotonic discharges were not observed. The patients also showed normal motor unit action potentials (see online supplementary figure S5). All of these findings suggested that the affected patients had evidence of peripheral sensory neuropathy but not motor neuropathy nor myopathy. The MMSE scores of patients III: 1, III: 9 and III: 11 from family 2423 were in the normal range (27--30): 28, 27 and 28, respectively with their corresponding educational backgrounds of junior college, high school and middle school. These normal scores (≥27) indicated normal cognitive function.

Re-examination of patients showed that both hearing impairment and sensory neuropathy slowly progress.[@R10] [@R25] Although serial cerebral MRI in familial ANSD demonstrated normal signal intensity in the brain, inclined sagittal MRI of the internal auditory canals showed bilateral cochlea nerve hypoplasia (CNH), a finding consistent with the diagnosis of ANSD ([figure 4](#JMEDGENET2014102961F4){ref-type="fig"}A, B and [table 1](#JMEDGENET2014102961TB1){ref-type="table"}). No symptoms or signs of muscle wasting, weakness or atrophy were identified in *AIFM1* mutated patients, and muscle biopsy of the left gastrocnemius in an affected member of family 0223 (III: 2) revealed only a few atrophic myofibers ([figure 4](#JMEDGENET2014102961F4){ref-type="fig"}C--G). All patients with *AIFM1* mutations had normal serum levels of lactate dehydrogenase and creatine kinase.

![Brain MRI imaging and muscle biopsy immune-staining of the patient (III: 3) from family 0223. (A) Serial cerebral MRI with fluid-attenuated inversion recovery sequence demonstrates normal signal intensity in bilateral centrum semiovale (left panel) and periventricular and subcortical white matter (right panel). (B) Axial view of the cerebellopontine angle and the internal auditory canal (IAC) shows normal anatomy (left panel). The two white lines illustrate the plane prescribed for oblique plane sagittal images obtained perpendicular to the nerves of the IAC. The oblique plane sagittal image (3D-fast-spin echo sequence, middle panel) obtained on the left side demonstrates an abnormally small cochlea nerve (Cn, white arrow) but a normal size IAC with normal facial (Fn), superior (Vsn) and inferior (Vin) vestibular nerves (green arrows). The right Cn was symmetrically small (right panel, white arrow). (C--F) Immunohistochemical staining of muscle biopsy (left gastrocnemius) in patient III: 3 shows a few atrophic myofibers (H&E, C). No ragged red fibres (modified Gomori-trichrome, D), ragged blue fibres (succinate dehydrogenase, E) or targetoid fibres (nicotinamide adenine dinucleotide-tetrazolium reductase, F) are identified. There is no reduction or absence of cytochrome-*c*-oxidase histochemical reactions observed (G).](jmedgenet-2014-102961f04){#JMEDGENET2014102961F4}

Impact on protein structure {#s3d}
---------------------------

We evaluated the functional effects of the 11 amino acid substitutions identified in this study using Polyphen2, SIFT, PROVEAN and Mutation Assessor.[@R26] Nine variants were predicted to be likely pathogenic by at least three programs. (We considered the following predictions as pathogenic: Polyphen2, probably damaging; SIFT, damaging; PROVEA, deleterious; Mutation Assessor, medium/high functional impact). The exceptions, p.R422Q and p.I591M, were predicted pathogenic by two and one program, respectively ([figure 3](#JMEDGENET2014102961F3){ref-type="fig"} and online supplementary table S12). Structural comparison of wild-type versus mutated AIFM1 protein showed that mutations in the two flavin adenine dinucleotide (FAD) and reduced nicotinamide adenine dinucleotide (NADH) domains have greater impact on the protein surface than mutations in C-terminus (see online supplementary figures S6 and S7).

Histological findings {#s3e}
---------------------

Immunostaining of murine inner ear demonstrated ubiquitous localisation of AIFM1 in the inner, especially to the cytoplasm of IHC, OHCs and spiral ganglion neurons, consistent with a role in normal auditory function ([figure 5](#JMEDGENET2014102961F5){ref-type="fig"} and online [supplementary figure](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2014-102961/-/DC1)s S8--S9).

![Localisation of AIFM1 in the murine inner ear by immunostaining with a monoclonal AIFM1 antibody. (A) Organ of Corti whole-mount preparation demonstrates AIFM1 (red) localisation to the cytoplasm of inner hair cell (IHC) and outer hair cells (OHCs), as well as the surrounding tissue. (B) Control organ of Corti tissue labelled with only secondary antibody and phalloidin (green). (C) Spiral ganglion whole-mount preparation shows AIFM1 (red) staining in spiral ganglion neurons. (D) Control spiral ganglion tissue labelled with secondary antibody and phalloidin (green). The scale bar indicates 15 µm in panels A and B, and 10 µm in panels C and D. DAPI, 4′,6-diamidino-2-phenylindole dihydrochloride.](jmedgenet-2014-102961f05){#JMEDGENET2014102961F5}

Discussion {#s4}
==========

In 2006, we mapped a novel X-linked auditory neuropathy locus (AUNX1) to chrXq23-q27.3 in a large five-generation Chinese family.[@R10] Using WES and confirmatory segregation analysis, we now report a novel missense change, p.R451Q in *AIFM1*, as causally responsible for the phenotype in this family. Consistent with its playing a major role in ANSD, we have identified 10 other mutations in *AIFM1* in a cohort of familial and sporadic cases of ANSD of Chinese ethnicity. In all familial cases, the identified variants (p.T260A, p.L344F, p.R422W and p.R422Q) co-segregate with the auditory and peripheral sensory neuropathy. All 11 variants were absent in a screen of 500 normal-hearing, ethnicity-matched Chinese controls (750 X chromosomes) and 9 were classified as likely damaging by multiple bioinformatics programs (see online supplementary table S12). In aggregate, these data provide abundant compelling evidence to implicate *AIFM1* in X-linked recessive ANSD.

*AIFM1* encodes apoptosis-inducing factor 1, a flavoprotein located in the mitochondrial intermembrane space. AIFM1 has at least two functions.[@R31] First, as a caspase-independent death effector, it mediates caspase-independent programmed cell death when translocating from mitochondria to the nucleus upon apoptotic stimuli. And second, as an FAD-dependent NADH oxidoreductase, it plays an important role in oxidative phosphorylation, redox control and respiratory chain activity in healthy cells. To date, *AIFM1* mutations have been associated with a severe mitochondrial encephalomyopathy (COXPD6, MIM\# 300816; caused by p.R201del),[@R11] prenatal ventriculomegaly (caused by p.G308E)[@R12] and Cowchock syndrome (CMTX4, MIM\# 310490; caused by p.E493V).[@R13] Common features of these disorders are developmental disabilities such as mental retardation, motor dysfunction and muscle weakness, and abnormal MRI findings in brain.[@R11] The AUNX1 phenotype is very different from these other phenotypes, as is the location of the causal mutations in the protein (see online supplementary table S13 and figure S10).

Based on phenotypic variability, it has been suggested that AIFM-related diseases have differing pathogenic mechanisms.[@R34] In Cowchock syndrome, the p.E493V mutation alters the redox properties of the mutated protein, resulting in increased apoptosis.[@R13] In COXPD6, in comparison, the R201del mutation reduces activity of respiratory chain complexes I--V and increases caspase-independent programmed cell death.[@R11] Most of the 11 mutations identified in this study are located in the NADH and second FAD domains of AIFM1, which are essential for FAD-dependent NADH oxidoreductase.

Interestingly, in spite of the widespread expression of AIFM1 in murine inner ear, which is consistent with a role in normal auditory function, the mutated protein did not affect OHCs function as measured by distortion product otoacoustic emission responses ([figure 5](#JMEDGENET2014102961F5){ref-type="fig"} and online supplementary table S9). In addition, while some patients with *AIFM1* mutations had MRI-documented CNH, the onset of hearing problems was typically during adolescence, suggesting that the hypoplasia represents late-onset and not congenital degeneration (see online supplementary figure S10; [table 1](#JMEDGENET2014102961TB1){ref-type="table"}).[@R35] [@R36]

ANSD is known to be an extremely complex disease that has congenital and acquired forms. Extensive clinical testing and genetic research are invaluable to elucidate underlying mechanisms and sites of pathology.[@R37] Our finding of bilateral CNH in *AIFM1*-related ANSD implies that MRI screening may identify the site of lesion in some patients with this phenotype. Furthermore, it suggests that if CNH is an eventual common outcome cochlea implantation in patients with *AIFM1*-related ANSD may meet with limited success.[@R40] In most patients, we were able to diagnose the other aspect of the phenotype, peripheral sensory neuropathy, by clinical and neurophysiological testing, although the symptoms of sensory neuropathy may occur many months or even years after the auditory neuropathy (see online supplementary table S11).

In conclusion, our study identifies *AIFM1* as a new causal gene associated with X-linked auditory neuropathy and delayed peripheral neuropathy. These results expand the spectrum of *AIFM1*-associated diseases to include ANSD. Because female carriers are unaffected, *AIFM1* should be considered in small pedigrees with apparent autosomal recessive ANSD if X-linked inheritance cannot be excluded. Further studies are required to determine the long-term benefit these patients may receive from cochlear implantation.
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